IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
1.910
-0.080 (-4.02%)
At close: Mar 12, 2026, 4:00 PM EDT
1.951
+0.040 (2.12%)
After-hours: Mar 12, 2026, 4:36 PM EDT
IN8bio Market Cap
IN8bio has a market cap or net worth of $18.65 million as of March 12, 2026. Its market cap has increased by 0.88% in one year.
Market Cap
18.65M
Enterprise Value
10.92M
1-Year Change
0.88%
Ranking
Category
Stock Price
$1.91
Market Cap Chart
Since the IPO on July 30, 2021, IN8bio's market cap has decreased from $187.55M to $18.65M, a decrease of -90.05%. That is a compound annual growth rate of -39.34%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 11, 2026 | 19.43M | 96.89% |
| Dec 31, 2025 | 9.87M | -47.05% |
| Dec 31, 2024 | 18.64M | -68.76% |
| Dec 29, 2023 | 59.67M | 5.43% |
| Dec 30, 2022 | 56.60M | -31.25% |
| Dec 31, 2021 | 82.33M | -56.10% |
| Jul 30, 2021 | 187.55M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Daré Bioscience | 21.29M |
| Genenta Science | 20.27M |
| VYNE Therapeutics | 19.78M |
| Citius Pharmaceuticals | 19.41M |
| Pasithea Therapeutics | 19.10M |
| Intensity Therapeutics | 18.80M |
| Longeveron | 17.26M |
| Lexaria Bioscience | 16.89M |